OXB.L: Summary for OXFORD BIOMEDICA PLC ORD 1P - Yahoo Finance

UK Markets open in 52 mins.

Oxford BioMedica PLC (OXB.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
4.70+0.14 (+2.96%)
At close: 4:29PM BST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close4.56
Bid4.28 x 2513500
Ask6.00 x 11600000
Day's range4.56 - 4.79
52-week range2.98 - 6.25
Avg. volume4,921,797
Market cap144.73M
PE ratio (TTM)-782.50
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters - UK Focus27 days ago

    Novartis wins speedy U.S. review of new leukaemia drug

    A new leukaemia treatment from Novartis (IOB: 0QLR.IL - news) for children and young adults will get priority review from the U.S. Food and Drug Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take action within six months on Novartis's so-called chimeric antigen receptor T cell therapy, or CAR (HKSE: 0699-OL.HK - news) -T, in partnership with University of Pennsylvania researchers.

  • Fool.co.uklast month

    2 great ‘hidden’ shares for growth investors

    Here are two potential growth shares that might not be so obvious.

  • Business Wire10 months ago

    ROTH Capital Partners to Host 3rd Annual Healthcare Day in London on June 22, 2016

    NEWPORT BEACH, Calif.--(BUSINESSWIRE)-- Event to Feature One-on-One Meetings Between Institutional Investors and Senior Management Teams Representing Companies Focused on the Biotechnology, Medical Technologies ...